The University of California San Francisco has received Investigational Review Board (IRB) approval.
The single-arm, open-label and multi-center study will enroll up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma.
The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks.
OMS ElectroImmunotherapy utilizes OncoSec’s proprietary technology to deliver a DNA-based cytokine coded for the immune stimulatingagent interleukin-12, or DNA IL-12.
OncoSec president and CEO Punit Dhillon said with immune response results from this Phase II study expected in the second half of 2012, this study will validate the value of OMS ElectoImmunotherapy.